Associated Papers
Genomic characterization of tumor mutational burden-high breast carcinomas.
Vougiouklakis T et al.
Npj Precision Oncology, 2025
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
Park C et al.
Cancer Immunology, Immunotherapy : Cii, 2024
39105849 (PubMed )
Supplement: 262_2024_3782_MOESM1_ESM.pdf
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.
Fasching PA et al.
Npj Breast Cancer, 2024
39003306 (PubMed )
Supplement: 41523_2024_667_MOESM1_ESM.pdf
Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary.
Kolbinger FR et al.
Journal of Gastrointestinal Cancer, 2023
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.
Boyd DC et al.
Cancers, 2023
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H et al.
Frontiers in Oncology, 2022
36072793 (PubMed )
Supplement: Table_3.xlsx › somatic_alterations
NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.
Sun Y et al.
Science Advances, 2021
Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase.
Okawa Y et al.
Oncotarget, 2021
34316332 (PubMed )
Supplement: oncotarget-12-1540-s001.pdf
Molecular Alterations in Vaginal Melanomas: Report of 4 Cases and Literature Review.
Moran JMT et al.
The American Journal of Dermatopathology, 2021
Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.
Melloni G et al.
Cancers, 2019
Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma.
Bankov K et al.
Clinical and Translational Gastroenterology, 2018
29712892 (PubMed )
Supplement: 41424_2018_15_MOESM1_ESM.xlsx › SupplTable5
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N et al.
The Oncologist, 2014
Select a paper to view details